A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest

Biochem Biophys Res Commun. 2006 Feb 24;340(4):1224-8. doi: 10.1016/j.bbrc.2005.12.131. Epub 2006 Jan 5.

Abstract

Patients with pancreatic cancer have little hope for cure because no effective therapies are available. Sansalvamide A is a cyclic depsipeptide produced by a marine fungus. We investigated the effect of a novel sansalvamide A analogue on growth, cell-cycle phases, and induction of apoptosis in human pancreatic cancer cells in vitro. The sansalvamide analogue caused marked time- and concentration-dependent inhibition of DNA synthesis and cell proliferation of two human pancreatic cancer cell lines (AsPC-1 and S2-013). The analogue induced G0/G1 phase cell-cycle arrest and morphological changes suggesting induction of apoptosis. Apoptosis was confirmed by annexin V binding. This novel sansalvamide analogue inhibits growth of pancreatic cancer cells through G0/G1 arrest and induces apoptosis. Sansalvamide analogues may be valuable for the treatment of pancreatic cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Cell Cycle / drug effects*
  • Cell Line
  • Cell Proliferation / drug effects*
  • Cell Survival / drug effects
  • Depsipeptides / administration & dosage*
  • Dose-Response Relationship, Drug
  • Humans
  • Pancreatic Neoplasms / pathology*

Substances

  • Antineoplastic Agents
  • Depsipeptides
  • sansalvamide A